TSX VENTURE COMPANIES
BULLETIN V2026-1197
TELYRX HOLDINGS INC. ("TELY")
[formerly, Apolo V Acquisition Corp. ("AFV.P")]
BULLETIN TYPE: Name Change and Consolidation, Qualifying Transaction-Completed, Private Placement-Brokered, Graduation
BULLETIN DATE: April 2, 2026
TSX Venture Tier 2 Company
TSX Venture Exchange (the "Exchange") has accepted for filing TelyRx Holdings Inc.'s (formerly, Apolo V Acquisition Corp.'s, the "Company") Qualifying Transaction (the "QT") described in its Filing Statement dated March 24, 2026. As a result, at the opening on Tuesday, April 7, 2026, the Company will no longer be considered a Capital Pool Company.
Name Change and Consolidation
Pursuant to a resolution passed by shareholders of the Company on March 5, 2026, the Company consolidated its capital on the basis of 1 post-consolidation common share for every 30 pre-consolidation common shares. The name of the Company has also been changed to "TelyRx Holdings Inc."
The QT
Pursuant to the business combination agreement dated January 19, 2026, as amended pursuant to an amending agreement dated February 19, 2026 and further amended pursuant to a second amendment dated March 18, 2026 between the Company and TelyRx Inc., among others (collectively, the "Business Combination Agreement"), the Company has reorganized its share capital such that the common shares of the Company are now known as Subordinate Voting Shares ("SVS") and an additional class of shares, known as Proportionate Voting Shares ("PVS") has been created. Each SVS will entitle the holder to one vote per share and each PVS will entitle the holder to the number of votes equal to the number of SVS into which each PVS is convertible (namely 100 SVS). The Company has indirectly acquired all the issued and outstanding shares of TelyRx Inc. ("TelyRx") for a total of 17,472,593 SVS (excluding the SVS issued in the Private Placement - Brokered section below) and 224,967 PVS.
Private Placement - Brokered
Prior to the completion of the QT, TelyRx completed a brokered private placement of subscription receipts which have been exchanged into the following securities:
Financing Type: Brokered - Private Placement
Gross Proceeds: $35,911,170.
Offering: 7,980,260 SVS
Offering Price: $4.50 per SVS
Commissions in Securities: Shares Warrants
Agents (Aggregate) Nil 46,996
Commission Terms: Each non-transferable warrant is exercisable at $4.50 for a 2-year period,
Disclosure: Refer to the company's news release(s) dated April 1, 2026.
Number of Securities Issued and Outstanding
Following completion of the QT, a total of 26,353,729 SVS (including the SVS issued in the Private Placement - Brokered section above) and 224,967 PVS are issued and outstanding.
Graduation
The Exchange has been advised that the Company's SVS will be listed and commence trading on Toronto Stock Exchange (the "TSX") at the market opening on Tuesday, April 7, 2026 under the name "TelyRx Holdings Inc." with the symbol "TELY".
As a result of this Graduation, the Company's common shares will be delisted from the Exchange at the commencement of trading on TSX.
Please refer to the Original Listing bulletin issued by TSX dated April 2, 2026 for further information on the listing and the Filing Statement dated March 24, 2026, which is available on www.sedarplus.ca for details of the QT.
_______________________________________
|
|
